

Rakuten Medical

Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform.

About Rakuten Medical, Inc.

Company Name	Rakuten Medical, Inc.		
Co-CEO	Hiroshi Mikitani, Takashi Toraishi		
Office Location	Rakuten Medical, Inc.	San Diego, USA	Corporate and R&D HQ
Subsidiaries	Rakuten Medical K.K.	Tokyo, Japan	Asia Operations and Device R&D
	Rakuten Medical Europe, B.V.	Amsterdam, Netherlands	Europe Operations and Device Oversight
	Rakuten Medical Taiwan, Inc. ¹⁾	Taipei, Taiwan	Asia Strategy Development and Operation Support
	Medlight SA ²⁾	Ecublens, Switzerland	Device Development and Manufacturing
Founded	2010 (Aspyrian Therapeutics, Inc.)		
Business	Development, manufacturing and commercialization of drug and medical devices		
Employees	Approx. 230 (Including subsidiaries. As of April 2022)		

¹⁾ Rakuten Medical Taiwan Inc. is a subsidiary of Rakuten Medical Japan K.K.

²⁾ Medlight SA is an indirect wholly owned subsidiary of Rakuten Medical Inc.

Rakuten Medical History

2010	<ul style="list-style-type: none"> Founding of Aspyrian Therapeutics, Inc. in San Diego, California, U.S.
2011	<ul style="list-style-type: none"> Dr. Hisataka Kobayashi of the U.S. National Cancer Institute published a paper on photoimmunotherapy, the technology underlying Alluminox™ platform, in the journal, Nature Medicine
2013	<ul style="list-style-type: none"> Mickey was investor for Aspyrian Therapeutics, Inc. Additional seed founding from private investors was received Aspyrian Therapeutics, Inc. granted an exclusive license from the National Institutes of Health to develop and commercialize photoimmunotherapy
2015	<ul style="list-style-type: none"> Investigational New Drug Application (IND) filed for Phase 1/2a to evaluate RM-1929* in recurrent head and neck squamous cell carcinoma (rHNSCC) in U.S.
2017	<ul style="list-style-type: none"> Office opened in Tokyo, Japan
2018	<ul style="list-style-type: none"> Fast Track designation of RM-1929 in rHNSCC by Food and Drug Administration (FDA) Initiation of Phase 1 trial to evaluate RM-1929 in rHNSCC in Japan Initiation of Global Phase 3 trial to evaluate ASP-1929*) in rHNSCC Hiroshi Mikitani appointed as CEO
2019	<ul style="list-style-type: none"> Rebranded company name to Rakuten Medical, Inc. ASP-1929 in HNC received Sakigake designation by Min. of Health, Labour and Welfare (MHLW) in Japan Office opened in Taipei, Taiwan, and Amsterdam, Netherlands
2020	<ul style="list-style-type: none"> Submitted a Japanese Biological License Application (JBLA) for ASP-1929 under the Conditional Early Approval System (CEAS) and applied for Japan approval of the laser illumination system

Rakuten Medical

	<ul style="list-style-type: none">• Strategic alliance collaboration agreement with The University of Texas MD Anderson Cancer Center to advance Alluminox™ platform for cancer treatments• Multi-year agreement with Merck KGaA to receive cetuximab for production of ASP-1929• The acquisition of Medlight SA• Received marketing approval from MHLW for Rakuten Medical's first drug, Akalux® IV Infusion 250mg and medical device, BioBlade® Laser System
2021	<ul style="list-style-type: none">• Commercialization of Akalux® IV Infusion 250mg and BioBlade® Laser System in Japan• Acquired phthalocyanine dyes, including IRDye® 700DX, from LI-COR Biosciences• Joint development and commercialization agreement with Shimadzu Corporation to advance a medical device for use on the Alluminox™ platform• Nitin Nohria appointed as Chairman• Strategic Partnership with Karkinos Healthcare to expand the Reach of Novel Cancer Care in India• IND for RM-1995 in advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma
2022	<ul style="list-style-type: none">• Initiation of Phase 2 trial to evaluate ASP-1929 administered prior to standard of care surgical tumor resection in patients with operable primary or recurrent HNSCC or cuSCC

*RM-1929 and ASP-1929 are analogous. Extensive physiochemical studies show that they have comparable physical and chemical properties.

As of May 2022